Imprimis Pharmaceuticals (NASDAQ: IMMY) and Insys Therapeutics (NASDAQ:INSY) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.
This table compares Imprimis Pharmaceuticals and Insys Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings for Imprimis Pharmaceuticals and Insys Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Imprimis Pharmaceuticals presently has a consensus price target of $5.00, suggesting a potential upside of 160.42%. Insys Therapeutics has a consensus price target of $9.67, suggesting a potential upside of 37.70%. Given Imprimis Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Imprimis Pharmaceuticals is more favorable than Insys Therapeutics.
Institutional and Insider Ownership
11.1% of Imprimis Pharmaceuticals shares are held by institutional investors. Comparatively, 24.2% of Insys Therapeutics shares are held by institutional investors. 12.6% of Imprimis Pharmaceuticals shares are held by insiders. Comparatively, 67.9% of Insys Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
Imprimis Pharmaceuticals has a beta of -0.22, meaning that its share price is 122% less volatile than the S&P 500. Comparatively, Insys Therapeutics has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.
Valuation & Earnings
This table compares Imprimis Pharmaceuticals and Insys Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Imprimis Pharmaceuticals||$26.77 million||1.49||-$11.98 million||($0.61)||-3.15|
|Insys Therapeutics||$140.69 million||3.68||-$228.01 million||($3.15)||-2.23|
Imprimis Pharmaceuticals has higher earnings, but lower revenue than Insys Therapeutics. Imprimis Pharmaceuticals is trading at a lower price-to-earnings ratio than Insys Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insys Therapeutics beats Imprimis Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
Imprimis Pharmaceuticals Company Profile
Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.
Insys Therapeutics Company Profile
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company’s lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.
Receive News & Ratings for Imprimis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.